Clinical Trial Update: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread [Phase 1]

View source ↗

Summary

This Phase 1 trial examines abemaciclib (LY2835219) in combination with other therapies for metastatic breast cancer; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING